Search Results

than assays—they build true scientific partnerships that help teams get the most from their data and advance GPCR empowers scientists and organizations advancing GPCR biology and GPCR-targeted drug discovery.

As datasets expand and systems are tested under new conditions, interpretations often require adjustment What initially appears mechanistically clear can become more nuanced when additional experiments are AMA will take place: Thursday, February 26th at 12:00 PM EST You are invited to submit questions in advance The defining distinction is saturation: Saturation defines the allosteric boundary  — additional modulator Advance promising hits into mechanistic evaluation quickly Use statistics to arbitrate interpretation

Experiments advance. Data improves. Technical milestones are reached. They are strategic signals. 👉 When timelines stop being adjustable. 👉 When costs become hard to unwind assumptions have changed. 👉 They avoid revisiting earlier decisions because reversing them feels like admitting

Upcoming events: 12th Adhesion GPCR Workshop; GPCRnet International Symposium; 5th GPCRs Targeted Drug Corner has expanded to 30+ courses and three live AMAs covering binding, kinetics, efficacy, mechanism, ADME This initiative brings together field experts to advance collective understanding of how GPCR-mediated That means structured, searchable, expert-led training across levels and topics — without additional Premium Members also receive a 50%+ discount on Terry’s Corner , unlocking advanced pharmacology depth

Kenakin highlights the definitive role of patch clamp assays and how high-throughput adaptations have Hepatotoxicity: The Central Organ Challenge The liver, often receiving the highest concentration of orally administered Pharmacokinetic approaches are adapted, sometimes employing exotic carriers or solvents to maximize exposure enhance detection Unique pharmacokinetics may be required for robust toxicology In Silico Toxic Signals Advancements As GPCR science and pharmacological innovation accelerate, timely guidance from foundational to advanced

Rather than chasing potency alone, this session equips drug hunters with system-level thinking: how ADME Optimization is modular  — activity, ADME, and safety can be tuned independently.

Research advances. New initiatives start. Additional questions are explored. The strategic advantage lies in leadership attention, not precision.

When biotech positioning is unclear, founders are forced to adapt their message in every interaction. Over time, this constant adjustment drains confidence and momentum, even when the science is strong. The most damaging effect is subtle. ✅ Founders start adapting their message in real time , trying to The positioning does that work in advance. They respond to questions as they arise, adjusting emphasis depending on who is listening.

Built for growth means building a biotech team that can learn, adapt, and move forward together as the a few keep the company moving forward even when certainty is missing. 👉 They reframe the problem, adjust Do they freeze, escalate, or adapt? Survival-oriented candidates show adjustment, not frustration. 3️⃣ How they define responsibility: Pay They are the ones where individuals can decide, adapt, and move forward without waiting for perfect clarity

Even if the risk is manageable, not addressing it makes the fundraising process harder. other, fundraising conversations move faster and with less friction. ✅ For founders, this creates an advantage

When teams adopt structured decision cycles, consistent narrative checkpoints, and predictable timeline

Academic innovation moves discovery forward only when assays are validated, distributed, and adopted

The expert they admire is right there, but the fear of sounding unprepared wins. a Scientific Career Through Asking Better Questions in Science Late in the conversation, JB offers advice

But you do need a framework for identifying and addressing regulatory gaps early .

Furthermore, image-based data provide an additional check against off-target cytotoxicity or morphological Image-based validation adds interpretive power.   Visual displacement provides an additional confidence layer that traditional homogeneous binding assays

Premium: Sneak Peek Industry insights:  Lilly cuts Zepbound prices; Lilly hits $1T valuation; Novo advances Upcoming events:  Adhesion GPCR Workshop; GRC—Transporters, Ion Channels & GPCRs; MPGPCR Joint Satellite This is where system-level GPCR thinking  becomes a competitive advantage—long before a molecule reaches GPCR is a 501(c)(3) non-profit organization—your participation directly supports our mission to advance

If your pitch doesn’t address timing, portfolio alignment, or internal traction, the audience won’t do Instead of leading with technology, lead with the problem it addresses. ✅ Frame the situation in terms

The sections below synthesize the key topics addressed during the AMA and highlight the GPCR pharmacology Biased agonism introduces additional layers where one pathway may mimic “reflex-like” counterbalancing Kenakin  emphasized that the key advantage is not subtlety for its own sake—it’s bounded pharmacology For complex GPCR systems, this boundary is a strategic advantage: NAMs can only shift an agonist curve Kenakin  highlighted historical β-adrenergic cases where tachycardia appeared only once compounds reached

It started with curiosity, openness, and the humility to admit that better answers required better tools It fused them, creating a hybrid view of receptor signaling that has now been adopted by labs worldwide

visualize receptor localization, internalization kinetics, and ligand interactions in intact cells offers advantages Key scientific advantages include: Physiological Relevance Fluorescent ligand binding occurs in intact Looking ahead, combining HCS with advanced probe design, scalable analytics, and expert scientific support

Which neurons respond Which cell populations drive therapeutic benefit Where not  to target to avoid adverse

Why it matters: Cost, tolerance, and long-term side effects will define real-world adoption.

These adaptations underscore Schild’s resilience—it remains one of the few analytical frameworks flexible

But you do need to adapt them if you want your startup to scale .    

“There was a bit of luck,” she admits. It’s a competitive advantage. 🎧 Listen to the full episode:   Leadership, Luck, and GPCR Signaling 🔓

Adenine-derived scaffolds enabled selective adenosine receptor antagonists; tryptophan modifications dual-modality treatments with unified pharmacokinetics  (instead of juggling two separate drugs with mismatched ADME Informatics Expands the Search Space for Chemical Drug Matter Advances in chemoinformatics  introduced Advances in formulation and delivery have overcome earlier pharmacokinetic limitations. Peptide GPCR therapies now address obesity, diabetes, cancer, neuroendocrine disorders, inflammatory

As part of these updates, a pricing adjustment is planned for 2026 — the first since Premium launched partnerships with Celtarys Research  and Revvity are great examples — uniting innovation and application to advance resources like the podcast and blog to our Premium ecosystem and Foundry initiatives, our mission is to advance

Carlsson is Professor of Computational Biochemistry at Uppsala University and one of the strongest advocates Beyond Academia: Advising Biotech Carlsson’s collaborative philosophy has also found a place in the biotech Instead, he acts as an advisor, helping research teams decide where modeling can accelerate progress—and Science advances faster when people invest in fluency beyond their own silo . And for the next generation of researchers and biotech leaders, that is the real collaboration advantage

His early Adenosine 2A receptor work, in collaboration with Ken Jacobson, helped establish virtual screening Carlsson also runs a consulting arm  that advises drug discovery teams on GPCR modeling strategy. GPCR Premium Ecosystem  for advanced insights into structure-based modeling, ligand design, and experimental

. ✅ Insider guidance  on how real teams decide which GPCR programs to advance or kill. Kinetics isn’t an afterthought—it’s a competitive advantage . Advance: What Real Teams Do How do large pharma teams decide whether to advance or pause a GPCR program What happens inside Big Pharma when programs are paused or advanced.